Safety and efficacy of neo-adjuvant sequential dose-dense chemotherapy doublets combined with trastuzumab in patients with HER-2-positive early stage breast cancer

Breast J. 2008 Sep-Oct;14(5):506-7. doi: 10.1111/j.1524-4741.2008.00634.x. Epub 2008 Aug 13.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology*
  • Cohort Studies
  • Disease-Free Survival
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Genes, erbB-2*
  • Humans
  • Mastectomy / methods
  • Middle Aged
  • Neoadjuvant Therapy / methods*
  • Neoplasm Staging
  • Radiotherapy, Adjuvant
  • Risk Assessment
  • Survival Analysis
  • Trastuzumab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Trastuzumab